Skip to Main Content

Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

ChemoCentryx is being purchased for $52 per share, or a 116% premium to its Wednesday closing price.


The centerpiece of Amgen’s acquisition is a pill called Tavneos that treats patients with ANCA-associated vasculitis, an autoimmune disease that causes inflammation, blockage, and damage to small blood vessels. People with the disorder are at high risk for organ damage, often in the kidneys and lungs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.